The online revenue for the year-ago interval stood at Rs 531 crore and the income from operations was reported at Rs 2,259 crore.
Moreover, the board of administrators of the corporate has additionally introduced a dividend of Rs 30 per share for its shareholders for the monetary yr 2024-25. For the aim of the shareholders, the corporate has mounted July 25 because the report date.
Sequentially, the PAT rose by 12.28%, up from Rs 594 crore within the third quarter of FY25. Even on the income entrance, the corporate registered a ten.3% QoQ progress, climbing up from Rs 2,297 crore.
Additional, Divi’s Laboratories reported a consolidated complete revenue of Rs 2,671 crore for the quarter ended March 31, 2025, in comparison with Rs 2,382 crore in the identical quarter final yr.
For the present quarter, the corporate has a foreign exchange achieve of Rs 10 crore as towards a foreign exchange lack of Rs 2 crore for the corresponding quarter of the earlier yr.In the meantime, for the complete monetary yr 2025, the corporate’s PAT stood at Rs 2,191 crore, versus Rs 1,600 crore for the corresponding quarter of the earlier monetary yr, marking a progress of 36.9% YoY.Additionally learn: What does CLSA’s downgrade imply for IndusInd Financial institution’s future?
Relating to its capex packages, the corporate knowledgeable that its Unit III greenfield mission at Ontimamidi Village, close to Kakinada, Andhra Pradesh, has commenced business operations within the present quarter.
Divi’s Labs has capitalised belongings valuing Rs 1,118 crore throughout the monetary yr, of which Rs 755 crore pertaining to Unit-III at Kakinada.
On Friday, the shares of Divi’s Laboratories closed 1.16% larger at Rs 6,281.35 on the BSE.
(Disclaimer: Suggestions, ideas, views and opinions given by the specialists are their very own. These don’t symbolize the views of The Financial Occasions)
